CRNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Crinetics Pharmaceuticals Inc (CRNX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, favorable analyst ratings, and hedge fund buying momentum, making it a solid choice for long-term growth.
The MACD histogram is positive and expanding (0.326), indicating bullish momentum. The RSI is neutral at 63.409, and moving averages are converging, suggesting a potential breakout. Key resistance levels are at 36.242 and 37.22, with support at 34.661 and 33.08.
Hedge funds have significantly increased their buying by 448.61% over the last quarter.
Positive Phase 2 data for Atumelnant and long-term efficacy data for Palsonify in acromegaly patients.
Analysts maintain Outperform ratings with price targets ranging from $84 to $97, indicating significant upside potential.
Favorable competitive landscape due to delays in a competitor's entry into the U.S. market.
No recent congress trading data or insider buying trends.
Stock trend analysis predicts a potential short-term decline (-1.33% in the next week, -3.37% in the next month).
No financial data available for analysis.
Analysts are bullish on CRNX, with multiple Outperform ratings and price targets ranging from $84 to $97. Analysts highlight strong commercial potential for Palsonify and a growing endocrine portfolio as key drivers for future growth.
